Ole Vahlgren
Director/Board Member bei CAMURUS AB
Vermögen: 474 627 $ am 31.03.2024
Profil
Ole Vahlgren is currently the Chief Executive Officer at Aj Vaccines.
A.
He is also a Director at Camurus AB, Go-Pen ApS, and Blue Cell Therapeutics ApS.
Previously, he worked as the President & Chief Executive Officer at Otsuka Pharmaceutical Europe Ltd.
Mr. Vahlgren holds an MBA from Copenhagen Business School and a graduate degree from the Technical University of Denmark.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
CAMURUS AB
0,02% | 31.12.2022 | 10 000 ( 0,02% ) | 474 627 $ | 31.03.2024 |
Aktive Positionen von Ole Vahlgren
| Unternehmen | Position | Beginn |
|---|---|---|
| CAMURUS AB | Director/Board Member | 07.05.2020 |
Go-PEN Aps
 Go-PEN Aps Medical SpecialtiesHealth Technology Go-Pen ApS develops insulin pen. The Danish company was founded in 2019 by Ole Kjerkegaard Nielsen, Michael Ejstrup Hansen. Ole Kjerkegaard Nielsen has been the CEO since 2019. | Director/Board Member | - |
Aj Vaccines A/S
 Aj Vaccines A/S BiotechnologyHealth Technology Part of AJ Biologics Sdn. The private company is based in Copenhagen, Denmark. Bhd., AJ Vaccines A/S is a Danish pharmaceutical company that develops and manufactures vaccines against serious infectious diseases, as well as diagnostic and therapeutic solutions. The CEO of the company is Ole Vahlgren. | Chief Executive Officer | - |
| Blue Cell Therapeutics ApS | Director/Board Member | - |
Ehemalige bekannte Positionen von Ole Vahlgren
| Unternehmen | Position | Ende |
|---|---|---|
Otsuka Pharmaceutical Europe Ltd.
 Otsuka Pharmaceutical Europe Ltd. Medical DistributorsDistribution Services Otsuka Pharmaceutical Europe Ltd. markets drugs, nutraceuticals and other health care products manufactured by its Japan-based parent, Otsuka Pharmaceutical. Some of the company's nutraceutical products include Pocari Sweat-electrolyte replacement beverages, Calorie Mate-energy beverages and the Calcium. Otsuka also makes products for infants under the Bean Stalk name. Additionally, the company conducts pharmaceutical research focusing on gastroenterology, oncology, dermatology, ophthalmology and the cardiovascular system. The company was founded in 1998 and is headquartered in Uxbridge, UK | Chief Executive Officer | - |
Ausbildung von Ole Vahlgren
| Copenhagen Business School | Masters Business Admin |
| Technical University of Denmark | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| CAMURUS AB | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Otsuka Pharmaceutical Europe Ltd.
Otsuka Pharmaceutical Europe Ltd. Medical DistributorsDistribution Services Otsuka Pharmaceutical Europe Ltd. markets drugs, nutraceuticals and other health care products manufactured by its Japan-based parent, Otsuka Pharmaceutical. Some of the company's nutraceutical products include Pocari Sweat-electrolyte replacement beverages, Calorie Mate-energy beverages and the Calcium. Otsuka also makes products for infants under the Bean Stalk name. Additionally, the company conducts pharmaceutical research focusing on gastroenterology, oncology, dermatology, ophthalmology and the cardiovascular system. The company was founded in 1998 and is headquartered in Uxbridge, UK | Distribution Services |
Aj Vaccines A/S
Aj Vaccines A/S BiotechnologyHealth Technology Part of AJ Biologics Sdn. The private company is based in Copenhagen, Denmark. Bhd., AJ Vaccines A/S is a Danish pharmaceutical company that develops and manufactures vaccines against serious infectious diseases, as well as diagnostic and therapeutic solutions. The CEO of the company is Ole Vahlgren. | Health Technology |
Go-PEN Aps
Go-PEN Aps Medical SpecialtiesHealth Technology Go-Pen ApS develops insulin pen. The Danish company was founded in 2019 by Ole Kjerkegaard Nielsen, Michael Ejstrup Hansen. Ole Kjerkegaard Nielsen has been the CEO since 2019. | Health Technology |
| Blue Cell Therapeutics ApS |
